Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma
A Study of the Zanubrutinib With G-CHOP Regimens in the Frontline Treatment of Intermediate-high Risk Follicular Lymphoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Huilai Zhang, MD,PhD
- Phone Number: 0086-22-23359337
- Email: info@tjmuch.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion criteria.
- Histologically confirmed CD20 positive (+) follicular lymphoma, grade 1, 2, or 3a
- Have had no prior systemic treatment for lymphoma
- Meeting Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria for initiation of treatment
- 18-75 years old.
- ECOG Performance Status of 0-2 within 10 days prior to registration.
- Stage II, III, or IV by Ann Arbor staging system.
- defined as Intermediate-high risk by the follicular lymphoma international prognostic index (FLIPI) 1 or FLIPI 2.
Demonstrate adequate organ function as defined below; all screening labs to be obtained within 28 days prior to registration.
- Hematological: WBC≥3.5×109/L, Platelets ≥ 75×109/L,Absolute Neutrophil Count (ANC) ≥ 1.0×109/L,Hemoglobin (Hgb) ≥ 80 g/L
- Renal:Calculated creatinine clearance ≥ 50 mL/min
- Hepatic:Bilirubin ≤ 1.5 × upper limit of normal (ULN), AST/ALT ≤ 2.5×ULN
- Females of childbearing potential must be willing to abstain from vaginal intercourse or use an effective method(s) of contraception from the time of informed consent, during the study and for 6 months after the last dose of study drug(s). Males able to father a child must be willing to abstain from vaginal intercourse or to use an effective method(s) of contraception from initiation of treatment, during the study and for 3 months after the last dose of study drug(s). See the protocol.
- Life expectancy ≥6 months
- Sign (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study
Exclusion criteria:
- Known active central nervous system lymphoma or leptomeningeal disease
- Evidence of diffuse large B-cell transformation
- Grade 3b FL
- Concurrent malignancy or malignancy within the last 3 years (except for ductal breast cancer in situ, non-melanoma skin cancer, prostate cancer not requiring treatment, and cervical carcinoma in situ) whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen are not eligible for this trial
- Known history of human immunodeficiency virus (HIV), or active hepatitis C Virus, or active hepatitis B Virus infection, or any uncontrolled active significant infection, including suspected or confirmed John Cunningham (JC) virus infection
- Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any class 3 (moderate) or class 4 (severe) cardiac disease as defined by the New York Heart Association functional classification. Or left ventricular ejection fraction <50%;
- Neuropathy ≥grade 2
- Known history of human immunodeficiency virus (HIV), or active hepatitis C Virus, or active hepatitis B Virus infection, or any uncontrolled active significant infection
- Known pneumonia associated with idiopathic pulmonary fibrosis, machine (for example, occlusive bronchiolitis), history of drug induced pneumonia, or screening during the chest computed tomography (CT) showed active pneumonia
- Have serious neurological or psychiatric history, can't normal study, including dementia, epilepsy, severe depression and mania
- Patients who were deemed by the investigator to be ineligible for enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treatment arm
Induction: Zanubrutinib and G-CHOP 4-6cycles Maintenance: Zanubrutinib and Obinutuzumab 1 year |
Zanubrutinib, 160mg PO BID.on days 1-28 Induction treatment: 4-6cycles ; Maintenance: 1 year;
Induction treatment: Obinutuzumab (G), 1000mg, IV, D1/8/15 (C1), D1 (C2-4/6); for 4-6 cycles, 1 cycle = 28 days Maintenance: Obinutuzumab (G), 1000mg, IV, every 2 months for 1 year;
Prednisone (P), 100 mg, PO, D2-6;for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
Cyclophosphamide (C), 750 mg/m2, IV, D2; for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
Vincristine (O), 1.4 mg/m2 (maximum 2 mg), IV, D2; for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
Doxorubicin (H), 50 mg/m2, IV, D2; for 4-6 cycles for CHOP treatment ,1 cycle = 28 days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
CR (complete response) rate after induction (4 or 6 Cycles) by investigator (INV)
Time Frame: From enrollment to the end of treatment at cycle 4 or 6 (each cycle is 28 days)
|
Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria
|
From enrollment to the end of treatment at cycle 4 or 6 (each cycle is 28 days)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective Response rate after induction by investigator (INV)
Time Frame: From enrollment to the end of end of treatment at cycle 4 or 6 (each cycle is 28 days)
|
ORR is defined as the proportion of patients achieving complete response (CR) or partial response (PR), as determined by INV according to 2014 Lugano criteria
|
From enrollment to the end of end of treatment at cycle 4 or 6 (each cycle is 28 days)
|
|
Overall survival (OS)
Time Frame: From the date of cycle 1, day 1 to the date of death regardless of cause, assessed up to 3 years
|
Overall survival (OS) is defined as the duration from the date of initiation of the first cycle of treatment to the date of death because of any cause
|
From the date of cycle 1, day 1 to the date of death regardless of cause, assessed up to 3 years
|
|
Progression free survival (PFS)
Time Frame: From the date of cycle 1, day 1 to the date of death regardless of cause, assessed up to 3 years
|
-PFS defined as time from the date of enrollment to the date of first confirmed disease progression or death due to any cause, whichever occurs first, as determined by INV
|
From the date of cycle 1, day 1 to the date of death regardless of cause, assessed up to 3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, Follicular
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Protein Kinase Inhibitors
- Antibiotics, Antineoplastic
- Tyrosine Kinase Inhibitors
- Cyclophosphamide
- Prednisone
- Doxorubicin
- Vincristine
- Obinutuzumab
- Zanubrutinib
Other Study ID Numbers
Other Study ID Numbers
- TN-FL001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.